Pictet Asset Management Holding SA Has $24.75 Million Holdings in Disc Medicine, Inc. $IRON

Pictet Asset Management Holding SA trimmed its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 1.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 387,005 shares of the company’s stock after selling 7,369 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Disc Medicine were worth $24,745,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Arizona State Retirement System boosted its holdings in Disc Medicine by 2.2% during the 4th quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after acquiring an additional 144 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in Disc Medicine by 3.3% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after acquiring an additional 215 shares during the last quarter. Avanza Fonder AB increased its stake in shares of Disc Medicine by 14.1% in the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in Disc Medicine by 3.3% during the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after acquiring an additional 296 shares during the period. Finally, Alliancebernstein L.P. increased its position in shares of Disc Medicine by 1.7% during the third quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock valued at $1,622,000 after buying an additional 400 shares during the period. Institutional investors own 83.70% of the company’s stock.

Insider Buying and Selling at Disc Medicine

In related news, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the completion of the sale, the insider owned 52,173 shares in the company, valued at $3,663,588.06. This trade represents a 12.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO John D. Quisel sold 34,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total value of $2,387,140.00. Following the transaction, the chief executive officer owned 226,064 shares in the company, valued at $15,871,953.44. The trade was a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 85,000 shares of company stock valued at $5,956,865. 3.76% of the stock is owned by company insiders.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $74.95 on Thursday. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -11.32 and a beta of 0.97. The stock’s 50-day simple moving average is $69.08 and its 200-day simple moving average is $70.50.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, analysts expect that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Morgan Stanley increased their target price on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Wedbush restated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.